Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.
about
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerHLA-dependent tumour development: a role for tumour associate macrophages?Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasisThe blockade of immune checkpoints in cancer immunotherapyChimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironmentPreemptive donor apoptotic cell infusions induce IFN-γ-producing myeloid-derived suppressor cells for cardiac allograft protection.Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.CX3CR1 delineates temporally and functionally distinct subsets of myeloid-derived suppressor cells in a mouse model of ovarian cancerExpression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytesFunctional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell linesTargeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer.Macrophages in tumor microenvironments and the progression of tumors.Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiencyCirculating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and ExtentPhenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancerOvarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion.Lymphatics: at the interface of immunity, tolerance, and tumor metastasis.Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitorsModulation of cancer-specific immune responses by amino acid degrading enzymes.Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β.Calreticulin Release at an Early Stage of Death Modulates the Clearance by Macrophages of Apoptotic CellsArmored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment.Immunosuppressive mechanisms of regulatory dendritic cells in cancer.Myeloid-derived suppressor cells in ovarian cancer: friend or foe?
P2860
Q26996829-470DB011-845C-4565-AC08-4EB89A840751Q27022124-97A9A019-DA10-42B8-A0B9-F8275F530711Q27311601-B293A0BB-99F5-4155-A489-3B4C57E71FDBQ27860852-B85514EC-CE4A-4663-87DE-F26A4103466DQ33671344-7CDE951C-E2EB-4E93-BE89-E36AD1885824Q33850216-F27B77BE-7A2C-4E7C-9DCA-623DF6429AE7Q34072679-0730C211-3CE6-439A-AFCC-283C033118AFQ34414289-3A8985C7-5DF1-4E16-A561-09086A9DF488Q34609220-E10F452C-2BBA-4EDA-B6F7-967094CA2E42Q34664957-8C709883-154D-45F3-BFE8-732457826A0AQ35082018-D7063201-2712-4F68-B948-9459AA8E30A5Q35793791-956FE196-37FC-405C-BA8F-26678CE20E50Q35927462-48125770-A908-4610-86F2-6929AC229C22Q36065902-FA94ADE7-B220-46BE-9272-F6062C87A03AQ36607445-A81EB208-E69D-4B3C-8B27-4694C24EE30CQ36683267-CBBD036C-238C-46FD-B96D-7FCECBE44C3BQ37200471-84D7335C-8221-4730-9871-43D80C5F29DCQ37429892-55804F69-3C7C-4A77-90B0-7E8EAE8A2E79Q37875904-5A9AF88E-B2B3-4EB7-A544-A54214FCB1E3Q38073753-438740F0-054D-489E-9019-BD71E727824EQ38161367-E2213AC8-EA3E-4808-8A75-D557328F873AQ38218134-AD5CC815-E5AA-4721-AA48-C725D8909812Q39045520-6A0338C9-06F6-4D1D-9D7D-700E66045224Q40538846-B6D9D70D-A1C8-4BBD-AC6C-BBBDBAC5DC29Q41526188-8AD09C1B-2354-4A09-8B1D-39B8DB23F2A2Q41619752-D712ACC3-C334-4EDB-8D86-F4734288D58BQ42264428-8BF1209C-B8BA-4C5B-9AFC-34DF1CCD76CFQ43084328-782060A8-8203-4D88-AFB2-3D3F988B8C75Q52689050-F6CED2F9-3D65-475B-889C-2FCA11512A9D
P2860
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Murine ovarian cancer vascular ...... tivity for T cell suppression.
@en
Murine ovarian cancer vascular ...... tivity for T cell suppression.
@nl
type
label
Murine ovarian cancer vascular ...... tivity for T cell suppression.
@en
Murine ovarian cancer vascular ...... tivity for T cell suppression.
@nl
prefLabel
Murine ovarian cancer vascular ...... tivity for T cell suppression.
@en
Murine ovarian cancer vascular ...... tivity for T cell suppression.
@nl
P2093
P2860
P1433
P1476
Murine ovarian cancer vascular ...... tivity for T cell suppression.
@en
P2093
Anselmo Alonso
Brent Berwin
Mary Jo Turk
S Peter Bak
P2860
P304
P356
10.1016/J.MOLIMM.2008.08.266
P577
2008-09-27T00:00:00Z